Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer

Propranolol regulates angiogenesis in pre-clinical models and reduces distant breast cancer (BC) metastases observational studies. We assessed the feasibility of combining propranolol with neoadjuvant chemotherapy (NAC) patients BC. Women clinical stage II–III BC undergoing NAC [weekly paclitaxel × 12, followed by dose-dense adriamycin/cyclophosphamide (AC) 4] started 20 mg PO BID #1, increased to 80 extended release (ER) daily, as tolerated. The primary endpoint was assess feasibility, defined at least 75% having 80% adherence prescribed. Secondary endpoints included identifying safety, rate dose holds modification, reaching ER daily. proposed sample size patients. From November 2012 September 2015, ten were enrolled. Median age 50.5 years (range, 44–67). All had hormone receptor-positive/HER2-negative cancer. Three women grade I bradycardia that resulted a 1-week delay increasing dose. Ninety percent reached target dosing 70% took until night before surgery. Of 4 who dose-reduced propranolol, 1 Mean 96% (range: 91–100%). went Our results support (up ER) taxane/anthracycline-based chemotherapy.